Sutent Related Published Studies
Well-designed clinical trials related to Sutent (Sunitinib)
Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell
lung cancer: a lead-in study. [2012]
Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib. [2011.12]
Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. [2011.07]
An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. [2011.07]
Phase II study of sunitinib malate in patients with recurrent high-grade glioma. [2011.07]
Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial. [2011.04]
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. [2011.02.10]
SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer. [2010.12]
Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib. [2010.08.10]
Sunitinib malate for gastrointestinal stromal tumour in imatinib mesylate-resistant patients: recommendations and evidence. [2010.08]
Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib. [2010.05.25]
Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. [2010.05]
Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer. [2010.03]
Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis. [2010.02.16]
Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-{alpha} as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population. [2009.11]
Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. [2009.09.01]
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. [2009.08.01]
Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. [2009.07]
Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. [2009.01.20]
Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma. [2008.01.15]
Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design. [2007.12]
Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. [2007.07]
Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. [2007.03.01]
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. [2007.01.11]
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. [2006.10.14]
Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. [2006.03]
Well-designed clinical trials possibly related to Sutent (Sunitinib)
New treatment strategies in advanced neuroendocrine tumours. [2011.10.07]
Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis. [2011.06]
MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients. [2011.06]
Targeted therapies for thyroid tumors. [2011.04]
Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1. [2011.01]
Management of adverse events associated with the use of everolimus in patients
with advanced renal cell carcinoma. [2011]
Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup
analysis of Japanese patients from RECORD-1. [2011]
Pazopanib in renal cell carcinoma. [2010.12.15]
Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. [2010.11.15]
Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double Blind, Placebo Controlled Phase III Study. [2010.09.29]
Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. [2010.09.15]
Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma. [2010.01]
Pazopanib in renal cell carcinoma. [2010]
Everolimus: in advanced renal cell carcinoma. [2009.10.22]
Role of everolimus in the treatment of renal cell carcinoma. [2009.10]
Everolimus: in advanced renal cell carcinoma. [2009]
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. [2008.08.09]
Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. [2008.01.15]
Other research related to Sutent (Sunitinib)
Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients
with locally advanced clear cell renal cell carcinoma at high risk for disease
recurrence. [2012]
Randomised phase II trial of docetaxel and sunitinib in patients with metastatic
gastric cancer who were previously treated with fluoropyrimidine and platinum. [2012]
Randomized phase II trial of sunitinib on an intermittent versus continuous
dosing schedule as first-line therapy for advanced renal cell carcinoma. [2012]
A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized
multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule,
tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine
kinase inhibitor monotherapy. [2012]
Phase III study of nilotinib versus best supportive care with or without a TKI in
patients with gastrointestinal stromal tumors resistant to or intolerant of
imatinib and sunitinib. [2012]
Feasibility study of two schedules of sunitinib in combination with pemetrexed in
patients with advanced solid tumors. [2012]
Sunitinib for advanced pancreatic neuroendocrine tumors. [2011.12]
Response Rates and Adverse Effects of Continuous Once-daily Sunitinib in Patients with Advanced Renal Cell Carcinoma: A Single-center Study in Turkey. [2011.12]
RhoB mediates antitumor synergy of combined ixabepilone and sunitinib in human ovarian serous cancer. [2011.11.21]
A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC. [2011.11.11]
Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group. [2011.11]
Systematic Review of Escalated Imatinib Doses Compared with Sunitinib or Best Supportive Care, for the Treatment of People with Unresectable/Metastatic Gastrointestinal Stromal Tumours Whose Disease has Progressed on the Standard Imatinib Dose. [2011.10.06]
Sunitinib: in advanced, well differentiated pancreatic neuroendocrine tumors. [2011.10.01]
Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. [2011.09.06]
Economic evaluation of everolimus versus sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line sunitinib. [2011.09]
Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib. [2011.08.25]
Nilotinib is effective in imatinib and sunitinib resistant GIST: a case report. [2011.05]
Sunitinib and other targeted therapies for renal cell carcinoma. [2011]
Long-term response with everolimus for metastatic renal cell carcinoma refractory
to sunitinib. [2011]
Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced
to sunitinib and everolimus: a case study. [2011]
Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib. [2010.09.07]
Sunitinib for the treatment of metastatic renal cell carcinoma. [2010.09.01]
Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer. [2010.09]
Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. [2010.09]
Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. [2010.08.14]
Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer. [2010.08]
Sunitinib in patients with metastatic renal cell carcinoma: Birmingham experience. [2010.08]
Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. [2010.07.25]
Prolonged response to cytoreductive surgery and sunitinib in an elderly patient with synchronous multiple metastases from renal cell carcinoma. [2010.05]
Multicenter phase II randomized trial evaluating antiangiogenic therapy with
sunitinib as consolidation after objective response to taxane chemotherapy in
women with HER2-negative metastatic breast cancer. [2010]
A phase I study of sunitinib plus bevacizumab in advanced solid tumors. [2009.10.01]
Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. [2009.10]
Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. [2009.09.20]
Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. [2009.09.10]
Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate. [2009.09.03]
Pharmacological management of gastrointestinal stromal tumours: an update on the role of sunitinib. [2009.08.12]
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. [2009.08]
Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. [2009.08]
Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. [2009.07.24]
Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness. [2009.07.21]
Efficacy of sunitinib and radiotherapy in genetically engineered mouse model of soft-tissue sarcoma. [2009.07.15]
Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies. [2009.07]
Sunitinib treatment in patients with severe renal function impairment: a report of four cases by the Hellenic Cooperative Oncology Group. [2009.07]
Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-{alpha} as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population. [2009.06.23]
Diagnosis and management of hypertension in advanced renal cell carcinoma: prospective evaluation of an algorithm in patients treated with sunitinib. [2009.06]
Cardiac magnetic resonance imaging in sunitinib malate-related cardiomyopathy: no late gadolinium enhancement. [2009.06]
11C-acetate PET for early prediction of sunitinib response in metastatic renal cell carcinoma. [2009.05]
Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. [2009.02]
Sunitinib is superior to interferon alpha with respect to quality of life for patients with renal cell carcinoma. [2009.01]
Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma. [2009.01]
Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. [2009]
[Treatment with sunitinib and hypothyroidism--a case report and overview of literature] [2009]
Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib. [2008.12]
Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase-inhibition with sunitinib. [2008.11.24]
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. [2008.11.20]
Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. [2008.11.10]
Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. [2008.11.08]
|
